Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.
Market Dashboard
Molbio Diagnostics
ListedMainboardBook built Issue
Issue Price
₹768 to ₹807Face Value
₹1 Per Equity ShareIssue Size
₹939.70 Cr.Listing On
BSENSE
Live
Allotment Available
Check your individual allotment on the official registrar portal.
Grey Market
₹130
+16.11% Est. Listing Premium
Est. Listing Price₹937
Updated: 15 Aug 2026, 08:15
About Molbio Diagnostics IPO
Financial Health
Live Subscriptions
Updated: 11 Aug 2026, 13:25Tracking
Frequently Asked Questions
The public subscription window officially opens on 10 August 2026 and concludes at 5:00 PM IST on 12 August 2026.
As of the latest market information, the GMP is ₹130, indicating a 16.11% estimated listing premium. GMP is an unofficial market indicator and can change rapidly.
Shares are offered at ₹768 to ₹807. Retail investors must bid for at least 18 shares, requiring a block investment of ₹14,526.
The allotment has been detected as available in the Kfin Technologies Ltd. system. You can use the official registrar link on this page to check your individual status. Shares are scheduled to debut on the exchanges on 17 August 2026.
The registrar for this IPO is Kfin Technologies Ltd..
The issue size for Molbio Diagnostics is ₹939.70 Cr..
The current status of the Molbio Diagnostics IPO is Listed. This status is determined from the issue and listing timeline using Indian Standard Time.
No. GMP is unofficial and can move significantly before listing. The actual listing price may differ from the GMP-based estimate.